Glassia Purple Book BLA 125325

BLA number
125325
Proprietary names
Glassia
Proper names
Alpha-1-Proteinase Inhibitor (Human)
Applicant
Takeda Pharmaceuticals U.S.A., Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001GlassiaAlpha-1-Proteinase Inhibitor (Human)351(a)1GInjectionIntravenousSingle-Dose VialRxLicensed2010-07-01
002GlassiaAlpha-1-Proteinase Inhibitor (Human)351(a)4GInjectionIntravenousSingle-Dose VialRxLicensed2025-02-27
003GlassiaAlpha-1-Proteinase Inhibitor (Human)351(a)5GInjectionIntravenousSingle-Dose VialRxLicensed2025-02-27

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-08-01N002Glassia351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2025-08-01N003Glassia351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2022-04-01U001Glassia351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2021-05-01U001Glassia351(a)RxKamada Ltd.
2020-08-01R001Glassia351(a)RxKamada Ltd.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-08-01002Glassia351(a)RxLicensed2025-02-27
2025-08-01003Glassia351(a)RxLicensed2025-02-27
2020-08-01001Glassia351(a)RxLicensed2010-07-01